CXCR4 and rheumatoid arthritis: In summary, the minimal cytotoxicity of CB, coupled with its wide-ranging inhibitory effects on ex vivo production of inflammatory cytokines and its therapeutic efficacy demonstrated in vivo, indicates that the use of CB-like molecules to target CXCR4 could serve as a novel and promising therapeutic strategy for chronic inflammatory diseases, including rheumatoid arthritis.